 |
|
|
| Poster session: Acute Myeloid Leukemia - Therapy |
| Date: | Friday, 7 June 2002 |
| Time: | 17:15-18:45 |
| Room: | |
| 17:15-18:45 |
0502 |
|
|
Arsenic salvage is superior to chemotherapy and bone marrow transplantation for relapsed acute promyelocytic leukemia: ten years of experience from Hong Kong
K.W.A. Lie, W.Y. Au, R.H.S. Liang, C.S. Chim, S.K. Ma, C.H. Chan, Y.K. Mak, Y.T. Chen, J.C.C. So, Y.M. Yeung, S.F. Yip, L.G. Wong, J.C. Chan, H.S. Liu, Y.L. Kwong (Hong Kong, Hongkong)
| 17:15-18:45 |
0503 |
|
|
INTRAVENOUS BUSULFAN REDUCES TOXICITY ASSOCIATED WITH MYELOABLATIVE HEMATOPOIETIC TRANSPLANTATION IN PATIENTS WITH MYELOID MALIGNANCIES
A. Shimoni, B. Bielorai, I. Hardan, M. Yeshurun, A. Avigdor, A. Papatryphonos, A. Toren, A. Nagler (Tel-hashomer, Israel)
| 17:15-18:45 |
0504 |
|
|
RESTING ACUTE MYELOID LEUKEMIA CELLS IN G0 PHASE OF THE CELL CYCLE, WHICH ARE RESISTANT TO CONVENTIONAL CHEMOTHERAPY ARE SENSITIVE TO GM-CSF/DIPHTERIA TOXIN FUSION PROTEINS
I. Jedema, R.M.Y. Barge, A.E. Frankel, R. Willemze, J.H.F. Falkenburg (Leiden, The Netherlands)
| 17:15-18:45 |
0505 |
|
|
A NOVEL EFFECTIVE AND SAFE CONSOLIDATION REGIMEN FOR ELDERLY PATIENTS WITH AML: INTERMITTENT INTERMEDIATE DOSE ARA-C (IDAC)
W.R. Sperr, M. Piribauer, F. Wimazal, C. Fonatsch, R. Thalhammer-Scherrer, I. Schwarzinger, K. Geissler, K. Lechner, P. Valent (Vienna, Austria)
| 17:15-18:45 |
0506 |
|
|
High dose Chemotherapy (HD CHT) followed by Autologous PBPC Transplant in elderly ANLL patients: outcome and impact of cytogenetic
D. Capelli, A. Poloni, G. Discepoli, M. Montanari, R. Centurioni, D. Massidda, M. Brunori, N. Manna, M. Catalini, M. Lucesole, L. Spitaleri, G. Gini, P. Leoni, A. Olivieri (Torrette Di Ancona, Italy)
| 17:15-18:45 |
0507 |
|
|
GENTUZUMAB OZOGAMICIN FOLLOWED BY STANDARD CHEMOTHERAPY FOR REMISSION INDUCTION IN PATIENTS 61-75 YEARS OLD WITH PREVIOUSLY UNTREATED AML: INTERIM RESULTS OF THE EORTC-LG AML-15A PHASE II TRIAL
S.A. Amadori, R. Willemze, S. Suciu, F. Mandelli, D. Selleslag, R. Stauder, A. Ho, C. Denzlinger, G. Leone, G. Fillet, P. Muus, J. Feingold, F. Beeldens, O. Anak, T. De Witte (Rome, Italy)
| 17:15-18:45 |
0508 |
|
|
PRE-INDUCTION CYTOREDUCTION WITH HYDROXYUREA IN ADULT PATIENTS WITH ACUTE LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS
M.P. Protivankova, J. Mayer, Y. Brychtova, M. Doubek (Brno, Czech Republic)
| 17:15-18:45 |
0509 |
|
|
PROLONGED ADMINISTRATION OF ALL-TRANS RETINOIC ACID (ATRA) WITH CHEMOTHERAPY AND GCSF IN ADULT ACUTE MYELOID LEUKEMIA (AML): SINGLE-CENTRE, PILOT STUDY IN DIFFERENT RISK GROUPS
R. Bassan, B. Chiodini, E. Oldani, A. Rambaldi, T. Barbui (Bergamo, Italy)
| 17:15-18:45 |
0510 |
|
|
SEQUENTIAL HIGH-DOSE CYTARABINE, IDARUBICIN AND GCSF (S-HAIG) FOR PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA (R-AML): CONSISTENCY OF SINGLE-CENTER VS. COLLABORATIVE TRIAL RESULTS
A. Grassi, E. Oldani, P. Fabris, G. Rossi, E. Pogliani, F. Marmont, T. Barbui (Bergamo, Italy)
| 17:15-18:45 |
0511 |
|
|
ACTIVATION STATUS-RELATED SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO ANTI-CD33-CALICHEAMICIN (GEMTUZUMAB OZOGAMICIN) CAN BE INCREASED BY INTERFERON GAMMA TREATMENT
I. Jedema, R.M.Y. Barge, V.H.J. van der Velden, J.G. te Marvelde, R. Willemze, J.H.F. Falkenburg, J.J.M. van Dongen (Leiden, The Netherlands)
| 17:15-18:45 |
0512 |
|
|
Multidrug resistance (MDR)-related protein 1 (MRP1) and lung resistance protein (LRP) are not the main drug resistance mechanisms of gemtuzumab ozogamicin (CMA-676) in AML
K. Naito, A. Takeshita, H. Matsui, T. Horie, M. Maekawa, K. Ohnishi, R. Ohno (Hamamatsu, Japan)
| 17:15-18:45 |
0513 |
|
|
POTENTIAL FOR THERAPY WITH LEUKEMIC DENDRITIC CELLS DERIVED FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA
M.M. Mohty, D. Blaise, D. Isnardon, D. Olive, B. Gaugler (Marseille, France)
| 17:15-18:45 |
0514 |
|
|
G-CSF as targeted induction therapy in acute myeloid leukemia with t(8;21)
F. Ferrara, E.M. Schiavone, G. Mele, S. Palmieri, C. Copia, F. Pollio, G. Scalia, L. Del Vecchio (Napoli, Italy)
| 17:15-18:45 |
0515 |
|
|
RESULTS OF TWO CONSECUTIVE TRIALS IN APL TREATMENT FROM RUSSIAN LEUKEMIA COOPERATIVE GROUP
E.N. Parovitchnikova, V.G. Savchenko, I.A. Demidova, V.G. Isaev, Yu.V. Olshanskaya, T.S. Konstantinova, V.A. Lapin, T.N. Perekatova, V.V. Cherepanova, G.B. Rehtman, N.A. Obidina, V.A. Tumakov, E.A. Belousov, G.I. Milyutina, L.N. Jeltuhina (Moscow, Russian Federation)
| 17:15-18:45 |
0516 |
|
|
AUTOLOGOUS STEM CELL TRANSPLANTATION IS A HIGHLY EFFECTIVE POST-REMISSION THERAPY IN PATIENTS WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA: LONG TERM FOLLOW UP OF 20 CASES
L Melillo, M.M. Minervini, N. Cascavilla, G. Perla, C.A. Bodenizza, M. Dell'Olio, A. Falcone, S. Mantuano, P. Musto, M. Nobile, G. Sanpaolo, A.M. Carella (S. Giovanni Rotondo, Italy)
| 17:15-18:45 |
0517 |
|
|
DIFFERENTIAL RESPONSE OF HUMAN MYELOID LEUKAEMIA CELLS TO THE ANTIBODY-TARGETED CHEMOTHERAPY MYLOTARG
D. Amico, A. Barbui, T. Barbui, E. Erba, A. Rambaldi, M. Introna, J. Golay (Milano, Italy)
| 17:15-18:45 |
0518 |
|
|
Therapy-related acute myeloid leucemias and myelodysplastic syndromes
J.D.T. Dwilewicz-Trojaczek, K. Madry, G. Charlinski, M. Paluszewska (Warsaw, Poland)
| 17:15-18:45 |
0519 |
|
|
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH CHEMOTHERAPY ALONE OR WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
- LONG-TERM FOLLOW UP
Lj. Tukic, D. Stamatovic, O. Tarabar, L. Ristic, Z. Tatomirovic, B. Todoric-Zivanovic, O. Tasic, B. Balint, M. Malesevic (Belgrade, Yugoslavia)
| 17:15-18:45 |
0520 |
|
|
EXPERIENCE WITH TRISENOX TM (ARSENIC TRIOXIDE) IN FRANCE
F. Garzon, C. Paradise, B. Kirkhart, J. Singer (Seattle, United States of America)
| 17:15-18:45 |
0521 |
|
|
Gemtuzumab Ozogomycin (GO) in combination with standard induction or consolidation therapy in adult Acute Myeloid Leukaemia (AML)
J. Kell, A.K. Burnett, R. Chopra, J. Lin, R. Clarke, D. Culligan, A. Hunter, A. Rohatiner, A. Prentice (Cardiff, United Kingdom)
| 17:15-18:45 |
0522 |
|
|
Cooperative analysis of core binding factor acute myeloid leukaemia treated in the German multicenter treatment trials AML 2/95 (SHG Hannover) and AML HD 93 (AMLSG ULM)
R.S Schlenk, A. Ganser, J. Krauter, K. Döhner, H. Döhner, G. Heil (Ulm, Germany)
| 17:15-18:45 |
0523 |
|
|
Hyperleukocytosis in Patients with Newly-Diagnosed Acute Myeloid Leukemia: Clinical Implications and Consequences of Leukapheresis To Reduce the Tumor Burden
R. Powles, B. Sirohi, S. Singhal, S. Kulkarni, S. Goyal, S. Sankpal, C. Horton, R. Saso, J. Mehta (Surrey, United Kingdom)
| 17:15-18:45 |
0524 |
|
|
Early recovery of total White Cell (WBC) count is an independent prognostic predictor for outcome in new patients with AML treated with intensive induction therapy-single centre study of 103 patients
R. Powles, B. Sirohi, S. Kulkarni, J. Treleaven, S. Goyal, S. Sankpal, R. Saso, C. Horton (Surrey, United Kingdom)
| 17:15-18:45 |
0525 |
|
|
Oral chemotherapy in acute myeloid leukemia and high-risk myelodisplasia in the elderly: clinical and organizative results of a coordinated, non-hematological network for community based-treatment
D.B.E. Di Bona, A. D'Emilio, F. Rodeghiero, G. Foscolo, S. Castronovo, O. Fontanive, G. Foscolo, F. Gaion, E. Ramazzina (Vicenza, Italy)
| 17:15-18:45 |
0526 |
|
|
THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS WITH MITOZANTRONE, ETOPOSIDE AND LOW-DOSE CYTARABINE - POLISH ACUTE LEUKEMIA GROUP (PALG) PHASE II STUDY
A. Wrzesie, T. Robak, K. Jamroziak, A. Wierzbowska, A. Dmoszynska, K. Kuliczkowski, J. Holowiecki, L. Konopka, S. Maj (Lodz, Poland)
| 17:15-18:45 |
0527 |
|
|
COMBINATION OF LIPOSOMAL DAUNORUBICIN, FLUDARABINE AND CYTARABINE (FLAD) IN PATIENTS WITH POOR RISK ACUTE LEUKEMIA
M.C. CLAVIO, I. Pierri, C. Venturino, V. Galbusera, S. Quintino, R. Varaldo, G. Beltrami, F. Ballerini, G.L. Michelis, E. Balocco, L. Canepa, M. Miglino, R. Cerri, S. Gatto, M. Gobbi (Genova, Italy)
| 17:15-18:45 |
0528 |
|
|
REPORT OF THE SAFETY AND EFFICACY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG®) GIVEN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: PHASE I
D. Russo, D. DeAngelo, S. Castaigne, J. Esteve, A. Burnett, A. Goldstone, M. Tallman, K. Bradstock, B. Lowenberg, L Leopold, M. Munteanu, C. Eten, M. Berger (Udine, Italy)
| 17:15-18:45 |
0529 |
|
|
ATTEMPTS TO IMPROVE INDUCTION TREATMENT IN AML PATIENTS UNDER 60 YEARS: THE IMPACT OF MITOXANTRONE; ARA-C DOSE AND RETINOID ACID: Results of MRC AML12
A.K.B. Burnett, K. Wheatley, A.H. Goldstone, A. Prentice (Cardiff, United Kingdom)
| 17:15-18:45 |
0530 |
|
|
OPTIMISING CONSOLIDATION THERAPY: FOUR VERSUS FIVE COURSES SCT VERSUS CHEMOTHERAPY - PRELIMINARY RESULTS OF MRC AML12
K. Wheatley, A.K. Burnett, B Gibson, A.H. Goldstone, D. Webb, A. Prentice, D. Milligan (Birmingham, United Kingdom)
| 17:15-18:45 |
0531 |
|
|
INDUCTION OF STABLE DISEASE BY TREATMENT WITH THE RECEPTOR TYROSINE KINASE INHIBITOR SU5416 IN A CHILD WITH ACUTE MYELOID LEUKAEMIA (AML) REFRACTORY TO STANDARD CHEMOTHERAPY
L.H. Meyer, A. Mohr, K. Stahnke, C.F. Classen, F. Bosse, C. Denzer, B. Praefke, P. Scigalla, K.M. Debatin (Ulm, Germany)
| 17:15-18:45 |
0532 |
|
|
OUTCOME OF PATIENTS UNDER 60 WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) TREATED AT A SINGLE CENTRE
K.M Scatchard, A.Z.S. Rohatiner, S. Slater, M. Cambal- Parrales, J. Amess, T.A. Lister (London, United Kingdom)
| 17:15-18:45 |
0533 |
|
|
FLAG-IDA IN THE TREATMENT OF REFRACTORY/ RELAPSED ACUTE MYELOID LEUKEMIA(AML): REPORT IN A SINGLE INSTITUTION
D. Pastore, G. Specchia, P. Carluccio, R. Rizzi, G. Mele, C. Buquicchio, G. Guaragna, S. Sibilla, V. Liso (Bari, Italy)
| 17:15-18:45 |
0534 |
|
|
CLINICAL DEVELOPMENT OF NON-MYELOABLATIVE TRANSPLANTS: APPLICATION AS INTEGRATED TREATMENT STRATEGY
M. van Hoef (Alexandria Va, United States of America)
| 17:15-18:45 |
0535 |
|
|
Post-remissional treatment of acute myelogenous leukemia: compliance to transplant procedures and follow-up
G.M. Giovanna Meloni, R.L. Roberto Latagliata, M.L.D. Maria Laura Dessanti, M.C.P. Maria Concetta Petti, W.A. William Arcese, S.C. Saveria Capria, S.M.T. Silvia Maria Trisolini, F.M. Franco Mandelli (Roma, Italy)
| 17:15-18:45 |
0536 |
|
|
Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplant (AlloHCT) with Thiotepa, Fludarabine and Melphalan Multiple Myeloma (MM)
I. Majolino, A. Severino, F. Blandino, M.R. Sajeva, C. Ruscio, A. Pandolfi, M. Gabriel-Arana, L. Pescador, A. Locasciulli (Rome, Italy)
|